Scholarlink

Background <p>Over the last decade, the pharmaceutical industry has witnessed longer, more complex, and expensive clinical trials. This complexity contributes to delays in clinical trial implementation, execution, monitoring, recruitment, data cleaning, and interpretation. Our aim was to develop a protocol complexity tool (PCT) to simplify clinical trial execution without compromising science or quality.</p> Methods <p>Using a collaborative design process, a taskforce comprising 20 cross-functional experts in clinical trial design and execution developed a PCT, between June 2021 and December 2022 and comprising 26 questions across 5 domains (operational execution, regulatory oversight, patient burden, site burden and study design). Individual domain scores and total complexity score (TCS) were calculated, and agreed by consensus, for 16 pre-identified phase II-IV difficult clinical trials across 3 therapeutic areas. Change in score was assessed post-PCT pass through. The relationship between TCS and key trial indicators (i.e. time-to-site activation and participant enrolment) was assessed for 26 studies by correlation analysis.</p> Results <p>Post-PCT pass through, the TCS was reduced in 12 trials (75%), remained the same in 3 trials (18.8%) and increased in 1 trial (6.2%). Complexity was most notably decreased in the operational execution and site burden domains, decreasing in 50% and 43.8% of assessed trials, respectively. Time-to-site activation and participant enrolment positively correlated with TCS, reaching statistical significance at 75% site activation (rho = 0.61; <i>p</i> = 0.005; <i>n</i> = 19) and 25% participant recruitment (rho = 0.59; <i>p</i> = 0.012; <i>n</i> = 17).</p> Conclusions <p>We have developed a Protocol Complexity Tool to objectively measure the complexity of a study protocol consistently and transparently. The PCT is capable of driving simplification, enhancing collaboration, and creating additional confidence in trial designs. In the future, we envision the tool will support earlier discussions to develop protocols that are simpler to execute and more cost-effective.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development of a protocol complexity tool: a framework designed to stimulate discussion and simplify study design

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月29日

查看全文
  • Bartholomeus J.A. Willigers,
  • Agata E Wiesiolek,
  • Bruce Potter,
  • Alina Pszczółkowska,
  • Cecilia Kristensson ,
  • Veronica Presz ,
  • Gabriela Luporini Saraiva,
  • Ioannis Psallidas

摘要

Background

Over the last decade, the pharmaceutical industry has witnessed longer, more complex, and expensive clinical trials. This complexity contributes to delays in clinical trial implementation, execution, monitoring, recruitment, data cleaning, and interpretation. Our aim was to develop a protocol complexity tool (PCT) to simplify clinical trial execution without compromising science or quality.

Methods

Using a collaborative design process, a taskforce comprising 20 cross-functional experts in clinical trial design and execution developed a PCT, between June 2021 and December 2022 and comprising 26 questions across 5 domains (operational execution, regulatory oversight, patient burden, site burden and study design). Individual domain scores and total complexity score (TCS) were calculated, and agreed by consensus, for 16 pre-identified phase II-IV difficult clinical trials across 3 therapeutic areas. Change in score was assessed post-PCT pass through. The relationship between TCS and key trial indicators (i.e. time-to-site activation and participant enrolment) was assessed for 26 studies by correlation analysis.

Results

Post-PCT pass through, the TCS was reduced in 12 trials (75%), remained the same in 3 trials (18.8%) and increased in 1 trial (6.2%). Complexity was most notably decreased in the operational execution and site burden domains, decreasing in 50% and 43.8% of assessed trials, respectively. Time-to-site activation and participant enrolment positively correlated with TCS, reaching statistical significance at 75% site activation (rho = 0.61; p = 0.005; n = 19) and 25% participant recruitment (rho = 0.59; p = 0.012; n = 17).

Conclusions

We have developed a Protocol Complexity Tool to objectively measure the complexity of a study protocol consistently and transparently. The PCT is capable of driving simplification, enhancing collaboration, and creating additional confidence in trial designs. In the future, we envision the tool will support earlier discussions to develop protocols that are simpler to execute and more cost-effective.